FDA approvals strengthen the case for differentiated specialty therapeutics

FDA approval of Hovilpri for refractory or resistant herpes lesions validates Asahi Kasei’s approximately $920 million AiCuris acquisition and creates a specialty anti-infective launch opportunity. Teva’s once-monthly Weltruza and Jaypirca’s expanded oncology approval reinforce formulation and targeted-therapy differentiation. Uptake, pricing, reimbursement, safety monitoring, and post-launch outcomes will determine whether these regulatory wins translate into durable returns.